1019034--3/26/2010--BIO_KEY_INTERNATIONAL_INC

related topics
{stock, price, share}
{product, market, service}
{control, financial, internal}
{system, service, information}
{customer, product, revenue}
{acquisition, growth, future}
{interest, director, officer}
{property, intellectual, protect}
{personnel, key, retain}
on our lack of significant revenue since inception and recurring losses from operations, our auditors have included an explanatory paragraph in their opinion as to the substantial doubt about our ability to continue as a going concern. Since our formation, we have historically generated minimal revenue and have sustained substantial operating losses. We have identified material weaknesses in our internal control over financial reporting. If we are unable to successfully address such material weaknesses, we may not be able to accurately report our financial results or prevent fraud. As a result, current and potential stockholders could lose confidence in our financial reporting; this would harm our business and the trading price of our common stock. technology has yet to gain widespread market acceptance and we do not know how large of a market will develop for our technology. Biometric technology is a new approach to Internet security must be accepted in order for our WEB-key solution to generate significant revenue. Our software products may contain defects which will make it more difficult for us to establish and maintain customers. In order to generate revenue from our biometric products, we are dependent upon independent original equipment manufacturers, system integrators and application developers, which we do not control. As a result, it may be more difficult to generate sales. We face intense competition and may not have the financial and human resources necessary to keep up with rapid technological changes, which may result in our technology becoming obsolete. We depend on key employees and members of our management team, including our Chairman of the Board and Chief Executive Officer, in order to achieve our goals. We cannot assure you that we will be able to retain or attract such persons. We cannot assure you that the intellectual property protection for our core technology provides a sustainable competitive advantage or barrier to entry against our competitors. We may need to obtain additional financing to execute our business plan, which may not be available. If we are unable to raise additional capital or generate significant revenue, we may not be able to continue operations. We may not achieve sustainable profitability with respect to the biometric component of our business if we are unable to maintain, improve and develop the wireless data services we offer. If we fail to adequately manage our resources, it could have a severe negative impact on our financial results or stock price. Our obligations to the holders of our outstanding preferred stock may adversely affect our ability to enter into potential significant transactions with other parties. Risks Related To Our Common Stock We have issued a substantial number of securities that are convertible into shares of our common stock which will result in substantial dilution to the ownership interests of our existing shareholders. A substantial number of our convertible securities are convertible into shares of common stock at a conversion price of $.30 per share. Most of these shares are eligible for public resale. The trading price of our common stock and our ability to raise additional financing may be adversely affected by the influx into the market of such a substantial number of shares. Applicable SEC Rules governing the trading of penny stocks limits the trading and liquidity of our common stock, which may affect the trading price of our common stock. We do not intend to pay dividends in the foreseeable future. The trading price of our common stock may be volatile. Completion of the Asset Sale may result in dilution of future earnings per share to the stockholders of BIO-key.

Full 10-K form ▸

related documents
1311318--4/1/2008--Lightspace_Corp
1311318--3/26/2007--Lightspace_Corp
1084000--6/13/2008--BIOPHAN_TECHNOLOGIES_INC
799097--4/17/2007--SAN_HOLDINGS_INC
1418475--10/14/2008--T.O.D._TASTE_ON_DEMAND_INC
75439--5/17/2010--CytoCore_Inc
1023966--7/30/2007--ISONICS_CORP
885317--3/31/2009--OPHTHALMIC_IMAGING_SYSTEMS
889423--3/12/2010--SATCON_TECHNOLOGY_CORP
277058--7/31/2006--NEVADA_GOLD_&_CASINOS_INC
1418730--3/17/2010--Industry_Concept_Holdings_Inc
1164554--3/16/2006--EUROBANCSHARES_INC
1164554--3/13/2008--EUROBANCSHARES_INC
1270200--3/31/2009--VIASPACE_Inc.
702513--3/5/2010--Bank_of_Commerce_Holdings
1164554--3/16/2007--EUROBANCSHARES_INC
1019034--3/11/2009--BIO_KEY_INTERNATIONAL_INC
1103837--3/29/2006--CROWN_MEDIA_HOLDINGS_INC
1108891--7/14/2009--LIGHTSCAPE_TECHNOLOGIES_INC.
1377720--4/15/2008--CYBERDEFENDER_CORP
1063197--4/5/2007--TORVEC_INC
1084557--3/31/2008--TASKER_PRODUCTS_CORP
821536--3/31/2006--HEARUSA_INC
797167--4/15/2008--NATURADE_INC
821536--3/28/2008--HEARUSA_INC
821536--4/6/2007--HEARUSA_INC
732412--3/31/2006--MULTIBAND_CORP
1090967--3/31/2008--GLOBAL_ENERGY_INC
1158419--3/30/2010--SPEEDEMISSIONS_INC
1158419--3/30/2009--SPEEDEMISSIONS_INC